Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0K2QG
|
|||
| Former ID |
DIB013626
|
|||
| Drug Name |
DASANTAFIL
|
|||
| Synonyms |
Dasantafil < USAN; SCH-446132; 7-(3-Bromo-4-methoxybenzyl)-1-ethyl-8-[2(R)-hydroxycyclopent-1(R)-ylamino]-3-(2-hydroxyethyl)-2,3,6,7-tetrahydro-1H-purine-2,6-dione; 7-(3-Bromo-4-methoxybenzyl)-1-ethyl-8-[2(R)-hydroxycyclopent-1(R)-ylamino]-3-(2-hydroxyethyl)xanthine
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Erectile dysfunction [ICD-11: HA01.1; ICD-10: N48.4; ICD-9: 302.72, 607.84] | Discontinued in Phase 2 | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C22H28BrN5O5
|
|||
| Canonical SMILES |
CCN1C(=O)C2=C(N=C(N2CC3=CC(=C(C=C3)OC)Br)NC4CCCC4O)N(C1=O)CCO
|
|||
| InChI |
1S/C22H28BrN5O5/c1-3-26-20(31)18-19(27(9-10-29)22(26)32)25-21(24-15-5-4-6-16(15)30)28(18)12-13-7-8-17(33-2)14(23)11-13/h7-8,11,15-16,29-30H,3-6,9-10,12H2,1-2H3,(H,24,25)/t15-,16-/m1/s1
|
|||
| InChIKey |
RCJYGWGQCPDYSL-HZPDHXFCSA-N
|
|||
| CAS Number |
CAS 569351-91-3
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Phosphodiesterase 5A (PDE5A) | Target Info | Inhibitor | [2] |
| KEGG Pathway | Purine metabolism | |||
| cGMP-PKG signaling pathway | ||||
| NetPath Pathway | TGF_beta_Receptor Signaling Pathway | |||
| Reactome | cGMP effects | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800018967) | |||
| REF 2 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.